Mediclinic International PLC (LON:MDC)‘s stock had its “neutral” rating reissued by Macquarie in a research report issued on Thursday. They presently have a GBX 660 ($8.71) price target on the stock. Macquarie’s price objective indicates a potential upside of 11.58% from the company’s current price.
Several other research analysts have also recently weighed in on the stock. Morgan Stanley cut shares of Mediclinic International PLC to an “equal weight” rating and dropped their price objective for the stock from GBX 825 ($10.89) to GBX 775 ($10.23) in a research report on Thursday, June 29th. Credit Suisse Group restated a “neutral” rating on shares of Mediclinic International PLC in a research report on Friday, July 21st. Jefferies Group LLC dropped their price objective on shares of Mediclinic International PLC from GBX 650 ($8.58) to GBX 550 ($7.26) and set an “underperform” rating for the company in a research report on Monday, September 25th. Citigroup Inc. dropped their price objective on shares of Mediclinic International PLC from GBX 790 ($10.42) to GBX 720 ($9.50) and set a “neutral” rating for the company in a research report on Wednesday, October 18th. Finally, J P Morgan Chase & Co cut shares of Mediclinic International PLC to a “neutral” rating and dropped their price objective for the stock from GBX 898 ($11.85) to GBX 733 ($9.67) in a research report on Thursday, October 19th. Two analysts have rated the stock with a sell rating and seven have issued a hold rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of GBX 665.33 ($8.78).
Mediclinic International PLC (MDC) opened at 591.50 on Thursday. The company has a 50-day moving average price of GBX 669.11 and a 200-day moving average price of GBX 743.61. Mediclinic International PLC has a one year low of GBX 587.50 and a one year high of GBX 941.50. The company’s market capitalization is GBX 4.36 billion.
TRADEMARK VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/28/mediclinic-international-plc-mdc-rating-reiterated-by-macquarie.html.
About Mediclinic International PLC
Mediclinic International plc is an international private healthcare provider. The Company’s segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services. It has interest in Spire Healthcare, a United Kingdom-based private healthcare company.
Receive News & Ratings for Mediclinic International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International PLC and related companies with MarketBeat.com's FREE daily email newsletter.